Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $723M (up 3.9% year over year) with net income of $62M.
Q1 2026 key financials · XBRL
- Revenue
- $723M
- +3.9% YoY
- Net income
- $62M
- +410.5% YoY
- Operating margin
- 19.6%
- Gross margin
- 44.3%
- EPS (diluted)
- $0.19
- +375.0% YoY
Source: XBRL data from the Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 10-Q on SEC EDGAR. USD.
Amneal Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Operating cash flow $(26.7)M vs $7.4M YoY, driven by $35.9M opioid settlement and $38.8M TRA payments
- Investing cash outflow $(21.7)M vs $(17.8)M YoY, reflecting higher acquisition-related deposits and intangible-asset purchases
- Financing cash outflow $(59.1)M vs $(39.2)M YoY, including $22.7M higher payroll-tax withholdings
- Kashiv acquisition expected second half of 2026, requiring $375M cash consideration funded through cash and borrowings
- Future commitments include $97.6M opioid payments through March 2034 and $75.0M MSN upfront payment in April 2026
Risk Factors
- New acquisition-completion risk triggered by April 21, 2026 Kashiv purchase agreement
- Regulatory risk from required stockholder and regulatory approvals potentially delaying or blocking Kashiv acquisition
- Strategic risk from anticipated Kashiv acquisition benefits failing to materialize at expected scale or timeline
- Financing risk indicated by February 2, 2026 term-loan credit agreement amendment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amneal Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.